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Background: Arginine vasopressin (AVP) is a hormone with vasoconstrictor, antidiuretic, and mitogenic properties. We hypothesized that plasma 
AVP levels are associated with left atrial size and left ventricular (LV) mass in adults.
Methods: We measured plasma levels of C-terminal pro-vasopressin (Copeptin) - a surrogate for circulating AVP - using an immunoluminometric 
assay. Participants included 1281 African Americans (65±9 y, 72% women) belonging to hypertensive sibships. Left atrial size and LV mass were 
assessed by 2-D echocardiography. LV mass was normalized for height to the power 2.7 (LVMi). Multivariable regression analyses (using generalized 
estimating equation) were used to assess whether plasma Copeptin was independently associated with left atrial size and LVMi.
Results: Plasma Copeptin was significantly correlated (Spearman) with left atrial size and LVMi (Figure). In separate regression analyses that 
adjusted for age, sex, body weight, estimated glomerular filtration rate, smoking, diabetes, medication (BP-lowering and statin) use, and systolic BP, 
log Copeptin was significantly associated with greater left atrial size (β±SE = 0.09±0.02, P < 0.0001) and log LVMi (β±SE = 0.03±0.01, P = 0.011).
Conclusions: Plasma Copeptin was independently associated with greater left atrial size and LVMi in an African American cohort enriched for 
hypertension. Our results motivate further study of the potential role of AVP in LV hypertrophy and AVP receptor blockade to regress LV hypertrophy.
